8-K: FOXO Technologies Inc. Secures Stockholder Approval for Potential Share Issuances

FOXO Technologies Inc. announces stockholder approval for potential issuances of common stock exceeding 20% to comply with NYSE American regulations.

Summary

• On February 27, 2025, FOXO Technologies Inc. received stockholder approval via written consent from a Majority Stockholder holding approximately 81% of the company's voting rights.
• The approval covers the potential issuance of Class A Common Stock to ClearThink Capital Partners, LLC for note conversions and exchanges, which could exceed 20% of outstanding shares.
• Approval was also granted for potential share issuances to investors in a private note offering up to $1,500,000, which could also exceed 20% of outstanding shares.
• Additionally, the Majority Stockholder approved the potential issuance of shares to Jefferson Street Capital, LLC for note conversions and commitment shares, potentially exceeding 20% of outstanding shares.
• These issuances are intended to comply with Section 713 of the NYSE American LLC Company Guide.
• The company filed a preliminary Information Statement on Schedule 14C with the SEC on February 28, 2025, and will mail the definitive statement to stockholders, with the approved items becoming effective 20 days after mailing.

Sentiment

Score: 5

Explanation: The announcement is neutral, detailing necessary approvals for potential financing activities. The potential dilution is a concern, but the financing could be beneficial if used effectively.

Positives

• The company is proactively addressing compliance with NYSE American regulations regarding potential share issuances.
• The approval from the Majority Stockholder provides FOXO Technologies Inc. with flexibility in securing financing through convertible notes and private offerings.

Negatives

• The potential issuance of a significant number of shares could dilute existing shareholders' equity.
• The reliance on convertible notes and private offerings may indicate challenges in accessing traditional financing sources.

Risks

• The actual issuance of shares is contingent on the company utilizing the approved private note offering and the conversion of notes by ClearThink Capital Partners, LLC and Jefferson Street Capital, LLC.
• Market conditions and investor sentiment could impact the company's ability to successfully execute these financing strategies.
• The dilution of existing shareholders' equity could negatively impact the stock price.

Future Outlook

The company intends to mail a definitive Information Statement on Schedule 14C to its stockholders, with the approved items becoming effective 20 days after mailing.

Industry Context

Many small-cap companies rely on convertible notes and private offerings for financing, especially in the biotechnology and technology sectors. Shareholder approval for issuances exceeding 20% is a standard requirement for NYSE American compliance.

Comparison to Industry Standards

• Similar companies like BioTime and Athersys have used convertible notes to raise capital.
• The potential dilution from these issuances should be compared to industry averages for companies in similar stages of development.
• The terms of the convertible notes, such as conversion price and interest rate, should be benchmarked against similar deals in the market.

Stakeholder Impact

• Shareholders may experience dilution if the company issues a significant number of new shares.
• The company's ability to secure financing could benefit employees and other stakeholders by ensuring continued operations.

Next Steps

• Mailing of the definitive Information Statement on Schedule 14C to stockholders.
• Potential issuance of shares upon conversion of convertible notes and utilization of the private note offering.

Key Dates